Kura Oncology
Kura Oncology's revenue rose 25.2% to $68 million in fiscal 2025. Its operating margin was −449.9%, down from −358.6% a year earlier. Free cash flow was −$71 million, against $134 million a year earlier. The diluted share count rose 1.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Kura Oncology does
Kura Oncology is a drug company that develops cancer medicines taken as pills. On November 13, 2025, the US Food and Drug Administration approved its first product, KOMZIFTI (ziftomenib), for adults with a type of blood cancer called relapsed or refractory acute myeloid leukemia (AML) that carries a specific gene change, called an NPM1 mutation, and who have no satisfactory alternative treatments. Kura says it is the first menin inhibitor approved by the FDA that is taken once a day by mouth.
Kura is still testing ziftomenib to see whether it works earlier in AML treatment and alongside other therapies, including in two late-stage trials in newly diagnosed patients. It is also testing it with imatinib for gastrointestinal stromal tumors. It has other programs: a next-generation menin inhibitor for diabetes and heart and metabolic conditions, and an experimental drug called darlifarnib that it is testing with other targeted therapies in solid tumors such as kidney, lung, colorectal and pancreatic cancers.
Kura says it has changed from a research company into a commercial-stage one, and it has little experience selling a drug. Its revenue will depend mostly on KOMZIFTI sales in the United States. It plans to move its drugs forward through its own development, partnerships and acquisitions.
Its biggest risks, as it describes them
- Its revenue depends heavily on successful sales of KOMZIFTI in the United States.
- KOMZIFTI may not win enough acceptance from doctors, patients and insurers, or its market may be smaller than expected.
- Limited experience as a commercial company, so selling the drug may go less well than planned.
- Losing or failing to widen its FDA approval, and results in real-world use that differ from its trials.
- Competing drugs, and the need to prove ziftomenib in combination and earlier-treatment settings.
Income statement
Kura Oncology lost money in fiscal 2025: a net loss of $279 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 518 | 438 | 424 | 727 | 667 |
| Debt incl. finance leases | — | 9 | 9 | 10 | 10 |
| Net debt (negative means net cash) | — | −429 | −415 | −718 | −658 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.0x | 0.0x | 0.0x | 0.1x |
| Interest coverage | −314.1x | −610.8x | −107.0x | −119.3x | −200.8x |
| Current ratio | 23.3x | 18.6x | 12.3x | 9.5x | 6.1x |
| Quick ratio | 23.3x | 18.6x | 12.3x | 9.5x | 6.0x |
Cash flow
Projections
Project Kura Oncology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Kura Oncology says to expect
- Collaboration revenue guidance: 2026 and later years
Kura has updated its 2026 collaboration revenue guidance to $40 million to $45 million for 2026 and is maintaining guidance of $90 million to $110 million in each of 2027 and 2028.
Insider trades
No officer, director or 10% owner of Kura Oncology reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 4 of 8 | 3 of 8 |
| Rule of 40 | — | — | −79.5% |
| Altman Z'' | 6.16 | 1.45 | −2.37 |
| Accruals ratio | −6.1% | −51.0% | −28.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | Pass | Fail |
| F-score | — | 4 of 8 | 3 of 8 |
Compare
Put Kura Oncology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Kura Oncology | FY25 | 25.2% | −449.9% | −104.8% | — | — | 3 | |
| Viridian Therapeutics | FY25 | 23,359.9% | −512.9% | −390.8% | — | — | — | Compare |
| Nuvation Bio | FY25 | 699.0% | −338.7% | −288.4% | — | — | — | Compare |
| Tango Therapeutics | FY25 | 48.3% | −178.4% | −224.3% | — | — | — | Compare |
| Eton Pharmaceuticals | FY25 | 104.9% | −1.1% | 12.8% | −1.9% | 1.4x | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | — | — | — | — | 0 | 54 | 68 |
| Revenue growth | — | — | — | — | — | — | — | — | — | 25.2% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | — | 26 | 47 | 48 | 60 | 85 | 93 | 115 | 170 | 251 |
| Operating income | — | — | — | — | — | — | −140 | −166 | −193 | −304 |
| Net income | −28 | −35 | −60 | −63 | −90 | −130 | −136 | −153 | −174 | −279 |
| Diluted EPS (US$) | −1.47 | −1.52 | −1.72 | −1.51 | −1.69 | −1.97 | −2.03 | −2.08 | −2.02 | −3.18 |
| Diluted shares (millions) | 19 | 23 | 35 | 42 | 53 | 66 | 67 | 73 | 86 | 88 |
| Cash flow | ||||||||||
| Cash from operations | −25 | −28 | −49 | −55 | −70 | −105 | −110 | −125 | 134 | −64 |
| Capital expenditure | — | — | — | — | 2 | 1 | 1 | 0 | 0 | 7 |
| Free cash flow | — | — | — | — | −72 | −106 | −111 | −125 | 134 | −71 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 4 | 9 | 9 | 13 | 24 | 26 | 28 | 34 | 37 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 10 | 93 | 179 | 237 | 633 | 518 | 438 | 424 | 727 | 667 |
| Debt incl. finance leases | 7 | 7 | — | 8 | 7 | — | 9 | 9 | 10 | 10 |
| Total assets | 70 | 96 | 182 | 242 | 647 | 534 | 456 | 449 | 760 | 738 |
| Total liabilities | 13 | 16 | 21 | 23 | 36 | 27 | 36 | 52 | 346 | 564 |
| Shareholders' equity | 57 | 80 | 161 | 219 | 611 | 507 | 420 | 397 | 414 | 174 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — | −358.6% | −449.9% |
| Net margin | — | — | — | — | — | — | — | — | −322.9% | −412.9% |
| Free cash flow margin | — | — | — | — | — | — | — | — | 248.4% | −104.8% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | −79.5% |
| Return on capital | — | −113.0% | — | — | — | — | — | — | — | — |
| Return on equity | −39.7% | −51.8% | −50.2% | −33.2% | −21.6% | −23.4% | −29.3% | −37.3% | −42.9% | −94.8% |
| Return on assets | −35.1% | −42.8% | −43.5% | −29.8% | −20.2% | −22.1% | −27.4% | −33.7% | −28.8% | −37.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |